Lenalidomide-C4-NH2 hydrochloride is a Cereblonligand derived from Lenalidomide. It serves as a recruiting agent for the CRBN protein. The compound, known as PROTAC (Compound 24), can be formed by linking Lenalidomide-C4-NH2 hydrochloride to the ligand for the protein. It exhibits inhibitory effects with IC50s of 0.98 nM and 13.7 nM against the growth of RS4;11 and MOLM-13 acute leukemia cell lines, respectively[1].
Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride is a chemical compound that features a cereblon (CRBN) ligand, functioning as an E3 ubiquitin ligase, along with a linker. It can be utilized to create the PROTAC MD-224[1].
Lenalidomide-propargyl-C2-NH2 hydrochloride is a compound that features a cereblon (CRBN) ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of the PROTAC MD-224[1] system.
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblonligand with a two-unit PEG linker for use in PROTAC technology[1].
Thalidomide-O-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that combines the cereblonligand derived from Thalidomide with a linker. It is commonly employed in the synthesis of PROTACs[1].
Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblonligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a chemical compound that has been synthesized as an E3 ligase ligand-linker conjugate. This compound incorporates a cereblonligand derived from Thalidomide and a 3-unit PEG linker. It is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].